BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ahmed AM, Doheim MF, Mattar OM, Sherif NA, Truong DH, Hoa PTL, Hirayama K, Huy NT. Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis. J Med Virol 2018;90:907-18. [PMID: 28892235 DOI: 10.1002/jmv.24947] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Skoreński M, Sieńczyk M. The Fellowship of Privileged Scaffolds-One Structure to Inhibit Them All. Pharmaceuticals (Basel) 2021;14:1164. [PMID: 34832946 DOI: 10.3390/ph14111164] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
2 Ghosh S, Samanta S, Ghosh AK, Neogi S, Hajra A. Advances in Oxosulfonylation Reaction. Adv Synth Catal 2020;362:4552-78. [DOI: 10.1002/adsc.202000647] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
3 Li Y, Gu Z, Xia J. Transition-Metal-Catalyzed Intermolecular C–H Carbonylation toward Amides. Synlett 2020;32:07-13. [DOI: 10.1055/s-0040-1706416] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
4 Ghosh AK, Mondal S, Hajra A. Dioxygen-Triggered Oxo-Sulfonylation of Hydrazones. Org Lett 2020;22:2771-5. [DOI: 10.1021/acs.orglett.0c00759] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
5 Zappulo E, Scotto R, Buonomo AR, Maraolo AE, Pinchera B, Gentile I. Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C. Expert Opin Pharmacother 2020;21:261-73. [PMID: 31914336 DOI: 10.1080/14656566.2019.1697674] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Wang X, Fan X, Deng H, Zhang X, Zhang K, Li N, Han Q, Lv Y, Liu Z. Efficacy and safety of glecaprevir/pibrentasvir for chronic hepatitis C virus genotypes 1-6 infection: A systematic review and meta-analysis. Int J Antimicrob Agents 2019;54:780-9. [PMID: 31284039 DOI: 10.1016/j.ijantimicag.2019.07.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
7 Schembri LS, Eriksson J, Odell LR. Palladium(0)-Catalyzed Carbonylative Synthesis of N -Acylsulfonamides via Regioselective Acylation. J Org Chem 2019;84:6970-81. [DOI: 10.1021/acs.joc.9b00740] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
8 Ye Q, Huang Y, Grier S, Miller SA. Oxidative degradation pathways of beclabuvir hydrochloride mediated by hydrogen peroxide and UV/Vis light. J Pharm Biomed Anal 2019;172:388-94. [PMID: 31100536 DOI: 10.1016/j.jpba.2019.05.017] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Esposito I, Marciano S, Trinks J. Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C. Expert Opin Drug Metab Toxicol 2018;14:649-57. [PMID: 29855221 DOI: 10.1080/17425255.2018.1483336] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]